Nick Pizzie's most recent trade in Axsome Therapeutics Inc was a trade of 33,000 Common Stock done at an average price of $3.5 . Disclosure was reported to the exchange on June 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 09 Jun 2026 | 33,000 | 75,867 (0%) | 0% | 3.5 | 115,500 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 240.09 per share. | 09 Jun 2026 | 33,000 | 42,867 (0%) | 0% | 240.1 | 7,922,970 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2026 | 33,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2026 | 8,188 | 8,188 | - | - | Performance Stock Units | |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 18,570 | 18,570 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 22 Jan 2026 | 12,000 | 54,588 (0%) | 0% | 3.5 | 42,000 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 187.92 per share. | 22 Jan 2026 | 12,000 | 42,588 (0%) | 0% | 187.9 | 2,255,040 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 12,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 9,516 | 9,516 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 9,423 | 9,423 | - | - | Performance Stock Units | |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 9,423 | 9,423 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 13 Feb 2025 | 12,000 | 54,187 (0%) | 0% | 3.5 | 42,000 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 129.86 per share. | 13 Feb 2025 | 12,000 | 42,187 (0%) | 0% | 129.9 | 1,558,320 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 131.07 per share. | 13 Feb 2025 | 3,000 | 42,187 (0%) | 0% | 131.1 | 393,210 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 13 Feb 2025 | 3,000 | 45,187 (0%) | 0% | 3.5 | 10,500 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 28,722 | 28,722 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Pizzie Nick | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 15,774 | 15,774 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 36,246 | 36,246 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 20,554 | 20,554 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 77,872 | 77,872 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 41,176 | 41,176 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 35.50 per share. | 18 Nov 2021 | 527 | 41,789 (0%) | 0% | 35.5 | 18,709 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 34.30 per share. | 18 Nov 2021 | 145 | 145 (0%) | 0% | 34.3 | 4,974 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 35.20 per share. | 18 Nov 2021 | 142 | 142 (0%) | 0% | 35.2 | 4,998 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 35.43 per share. | 18 Nov 2021 | 141 | 201 (0%) | 0% | 35.4 | 4,996 | Common Stock |
| Axsome Therapeutics Inc | Nick Pizzie | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2021 | 36,086 | 36,086 | - | - | Employee Stock Option (Right to Buy) |